Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2015 | original article | Ausgabe 7-8/2015

Wiener klinische Wochenschrift 7-8/2015

Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes

Results of the Austrian subpopulation of the EDGE study

Wiener klinische Wochenschrift > Ausgabe 7-8/2015
MD Dr. Helmut Brath, MD Dr. Christoph Bialek, MD Ewald Gingl, MD Michael Resl, MD Univ. Prof. Dr. Rudolf Prager, MD Michaela Ratzinger



The aim of this post hoc analysis of data from the Austrian subpopulation of the EDGE study was the evaluation of the effectiveness and tolerability of vildagliptin as an add-on to an existing oral antidiabetic (OAD) monotherapy versus a combination therapy with two OADs without vildagliptin in patients with inadequately controlled type 2 diabetes.

Patients and methods

In Austria, 422 patients were included. In the framework of regular visits (at baseline, about once per quarter, and at the study end, after 12 months), adverse events (AEs), courses, and changes of therapy were recorded. In addition to the primary end point defined in the primary study, i.e., a reduction of HbA1c by > 0.3 % without hypoglycemia, weight gain ≥ 5 %, peripheral edema, or discontinuation due to gastrointestinal events, the most clinically relevant secondary end point, i.e., HbA1c reduction < 7 % without hypoglycemia or ≥ 3 % increase in body weight after 12 months was used for the analysis of the Austrian data.


The initial HbA1c of all enrolled patients was 8.3 ± 1.4 %. The mean reduction of HbA1c was − 1.1 % in the vildagliptin cohort and − 1.0 % in the comparator cohort. In the vildagliptin cohort, 56.4 % of patients, and in the comparator cohort, 45.9 % of patients, reached the primary end point (odds ratio: 1.53, p = 0.04). In the vildagliptin cohort, 18.7 % of patients, and in the comparator cohort, 16.9 % of patients, reached the secondary end point (odds ratio: 1.13, p = 0.68). The incidence of hypoglycemic events (two in each cohort), AEs (approximately 15 % in each cohort), and serious AEs (approximately 2 % in each cohort) was comparable between the two groups.


In a “real-life” setting, the effectiveness of vildagliptin as second-line treatment is superior to comparator OADs with regard to a reduction in HbA1c of greater than 0.3 % from baseline without well-recognized side effects in patients with inadequately controlled type 2 diabetes (mean baseline HbA1c: 8.5 % (vildagliptin cohort) vs. 8.1 % (comparator cohort)).

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 7-8/2015

Wiener klinische Wochenschrift 7-8/2015 Zur Ausgabe

mitteilungen der gesellschaft


mitteilungen der gesellschaft der ärzte in wien

Mitteilungen der Gesellschaft der Ärzte in Wien